Brokerages Set GE HealthCare Technologies Inc. (NASDAQ:GEHC) PT at $98.75

GE HealthCare Technologies Inc. (NASDAQ:GEHC) has been given an average rating of “Moderate Buy” by the thirteen analysts that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have given a hold rating, nine have assigned a buy rating and one has issued a strong buy rating on the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $98.75.

GEHC has been the topic of several research reports. The Goldman Sachs Group upgraded GE HealthCare Technologies from a “neutral” rating to a “buy” rating and upped their price objective for the company from $85.00 to $100.00 in a research note on Tuesday, March 11th. Wells Fargo & Company upped their target price on GE HealthCare Technologies from $96.00 to $103.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Citigroup upped their target price on GE HealthCare Technologies from $103.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, February 13th. Finally, Jefferies Financial Group raised GE HealthCare Technologies from a “hold” rating to a “buy” rating and upped their target price for the company from $95.00 to $103.00 in a report on Wednesday, January 8th.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of GEHC. Norges Bank acquired a new stake in shares of GE HealthCare Technologies in the fourth quarter valued at approximately $488,531,000. D1 Capital Partners L.P. acquired a new stake in shares of GE HealthCare Technologies in the third quarter valued at approximately $268,159,000. Capital Research Global Investors increased its holdings in shares of GE HealthCare Technologies by 4.5% in the fourth quarter. Capital Research Global Investors now owns 60,832,004 shares of the company’s stock valued at $4,755,851,000 after purchasing an additional 2,608,066 shares in the last quarter. Van ECK Associates Corp grew its holdings in GE HealthCare Technologies by 107.3% during the 4th quarter. Van ECK Associates Corp now owns 4,841,652 shares of the company’s stock worth $378,520,000 after acquiring an additional 2,506,417 shares during the period. Finally, Vanguard Group Inc. grew its holdings in GE HealthCare Technologies by 4.3% during the 4th quarter. Vanguard Group Inc. now owns 52,537,446 shares of the company’s stock worth $4,107,378,000 after acquiring an additional 2,155,429 shares during the period. Institutional investors own 82.06% of the company’s stock.

GE HealthCare Technologies Trading Down 0.4 %

Shares of GEHC opened at $81.49 on Wednesday. The company has a current ratio of 1.04, a quick ratio of 0.83 and a debt-to-equity ratio of 0.88. The firm has a market capitalization of $37.27 billion, a P/E ratio of 18.82, a price-to-earnings-growth ratio of 3.19 and a beta of 1.13. The stock’s fifty day simple moving average is $87.02 and its 200 day simple moving average is $86.02. GE HealthCare Technologies has a twelve month low of $74.51 and a twelve month high of $94.80.

GE HealthCare Technologies (NASDAQ:GEHC) last released its quarterly earnings data on Thursday, February 13th. The company reported $1.45 EPS for the quarter, beating the consensus estimate of $1.26 by $0.19. GE HealthCare Technologies had a return on equity of 25.74% and a net margin of 10.13%. The company had revenue of $5.32 billion for the quarter, compared to analyst estimates of $5.33 billion. On average, equities research analysts forecast that GE HealthCare Technologies will post 4.68 earnings per share for the current year.

About GE HealthCare Technologies

GE HealthCare Technologies Inc engages in the development, manufacture, and marketing of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients in the United States, Canada, and internationally. The company operates through four segments: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics.